P19214 AF NFT

Erythrocyte-binding antigen 175

MOLNFT AF v1 smart contract in GenesisL1 blockchain: 
0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD
IPFS of NFT metadata: 
bafybeieiexi7da6a5u6dxvqtzrstc6hbzxqb7uwvg3cfz777z6c3dr5a7q/metadata.json
IPFS of structure file: 
bafybeifhs37fkobmzmjlvqar3mfpaoj6cnxu52bv2ba42ocmx7nb5gxskq/AF-P19214-F1-model_v2.pdb
First NFT owner address (eip-55): 
0x33b6Ad4112Beb5794007C1424D3b98Fd079D6DA2
First NFT owner address (bech32): 
genesis1xwm26sgjh66hjsq8c9py6wucl5re6mdz9fr63c
Current NFT ID #109346 owner (web3):

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
109346
Accession (UniProt):
P19214
Name::
Erythrocyte-binding antigen 175
Experimental Method:
Predicted structure
Sequence source:
Plasmodium falciparum (isolate Camp / Malaysia)

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT P19214 research and analysis (ICN3D with VR)

FASTA sequences

>sp|P19214|EBA1_PLAFC Erythrocyte-binding antigen 175 OS=Plasmodium falciparum (isolate Camp / Malaysia) OX=5835 PE=1 SV=2 MKCNISIYFFASFFVLYFAKARNEYDIKENEKFLDVYKEKFNELDKKKYGNVQKTDKKIFTFIENKLDILNNSKFNKRWKSYGTPDNIDKNMSLINKHNNEEMFNNNYQSFLSTSSLIKQNKYVPINAVRVSRILSFLDSRINNGRNTSSNNEVLSNCREKRKGMKWDCKKKNDRSNYVCIPDRRIQLCIVNLSIIKTYTKETMKDHFIEASKKESQLLLKKNDNKYNSKFCNDLKNSFLDYGHLAMGNDMDFGGYSTKAENKIQEVFKGAHGEISEHKIKNFRKEWWNEFREKLWEAMLSEHKNNINNCKNIPQEELQITQWIKEWHGEFLLERDNRSKLPKSKCKNNTLYEACEKECIDPCMKYRDWIIRSKFEWHTLSKEYETQKVPKENAENYLIKISENKNDAKVSLLLNNCDAEYSKYCDCKHTTTLVKSVLNGNDNTIKEKREHIDLDDFSKFGCDKNSVDTNTKVWECKNPYILSTKDVCVPPRRQELCLGNIDRIYDKNLLMIKEHILAIAIYESRILKRKYKNKDDKEVCKIINKTFADIRDIIGGTDYWNDLSNRKLVGKINTNSKYVHRNKKNDKLFRDEWWKVIKKDVWNVISWVFKDKTVCKEDDIENIPQFFRWFSEWGDDYCQDKTKMIETLKVECKEKPCEDDNCKSKCNSYKEWISKKKEEYNKQAKQYQEYQKGNNYKMYSEFKSIKPEVYLKKYSEKCSNLNFEDEFKEELHSDYKNKCTMCPEVKDVPISIIRNNEQTSQEAVPEENTEIAHRTETPSISEGPKGNEQKERDDDSLSKISVSPENSRPETDAKDTSNLLKLKGDVDISMPKAVIGSSPNDNINVTEQGDNISGVNSKPLSDDVRPDKKELEDQNSDESEETVVNHISKSPSINNGDDSGSGSATVSESSSSNTGLSIDDDRNGDTFVRTQDTANTEDVIRKENADKDEDEKGADEERHSTSESLSSPEEKMLTDNEGGNSLNHEEVKEHTSNSDNVQQSGGIVNMNVEKELKDTLENPSSSLDEGKAHEELSEPNLSSDQDMSNTPGPLDNTSEETTERISNNEYKVNEREDERTLTKEYEDIVLKSHMNRESDDGELYDENSDLSTVNDESEDAEAKMKGNDTSEMSHNSSQHIESDQQKNDMKTVGDLGTTHVQNEISVPVTGEIDEKLRESKESKIHKAEEERLSHTDIHKINPEDRNSNTLHLKDIRNEENERHLTNQNINISQERDLQKHGFHTMNNLHGDGVSERSQINHSHHGNRQDRGGNSGNVLNMRSNNNNFNNIPSRYNLYDKKLDLDLYENRNDSTTKELIKKLAEINKCENEISVKYCDHMIHEEIPLKTCTKEKTRNLCCAVSDYCMSYFTYDSEEYYNCTKREFDDPSYTCFRKEAFSSMIFKFLITNKIYYYFYTYKTAKVTIKKINFSLIFFFFFSF